DEF: Microbot Medical Seeks Stockholder Approval for Share Issuance and Increase in Authorized Shares

Microbot Medical is holding a special meeting to seek stockholder approval for issuing shares related to a recent offering and to increase the number of authorized shares of common stock.

Summary

• Microbot Medical is holding a special meeting of stockholders on April 11, 2025, to vote on three proposals.
• The first proposal seeks approval for the issuance of Series I preferred investment options and placement agent options, along with the underlying common stock, related to a securities offering completed on February 11, 2025.
• This approval is needed to comply with Nasdaq listing rule 5635(d) and fulfill contractual obligations.
• The second proposal involves amending the company's Certificate of Incorporation to increase the total number of authorized common stock shares.
• The third proposal requests approval to adjourn the special meeting, if necessary, to solicit additional proxies for the first two proposals.
• The board of directors unanimously recommends voting in favor of all three proposals.

Sentiment

Score: 6

Explanation: The document is primarily procedural, seeking approval for previously agreed-upon actions. While the dilution risk is a concern, the overall sentiment is neutral as the proposals are necessary for the company to move forward.

Positives

• Approval of the proposals would allow Microbot Medical to fulfill its obligations related to the recent securities offering.
• Increasing the authorized shares would provide the company with greater flexibility for future capital raising and strategic transactions.
• The board of directors unanimously recommends voting in favor of the proposals.

Negatives

• If the Issuance Proposal is not approved, the Options would not be exercisable and all obligations to facilitate the issuances of Options and the shares of our common stock underlying the Options would remain in effect and may result in obligations to which the Company may not have the resources to satisfy.
• If the Increase Proposal is not approved, the Options would not be exercisable and all obligations to facilitate the issuances of Options and the shares of our common stock underlying the Options would remain in effect and may result in obligations to which the Company may not have the resources to satisfy.
• Existing stockholders will experience dilution if the options are exercised.

Risks

• Failure to obtain stockholder approval for the Issuance Proposal could impair the value of the options and hinder the company's ability to raise capital.
• Failure to approve the Increase Proposal could limit the company's flexibility for future financing and strategic initiatives.
• The market price of the common stock could be adversely affected by the sale of shares issued upon exercise of the options.
• The company will incur substantial cost, and management will devote substantial time and attention, in attempting to obtain such approvals.

Future Outlook

The company intends to use the increased authorized shares for future capital raising, acquisitions, employee compensation, and other currently unanticipated uses.

Industry Context

This announcement reflects a common practice for companies seeking to raise capital and ensure compliance with Nasdaq listing rules, particularly regarding the issuance of shares and options exceeding 20% of outstanding shares.

Comparison to Industry Standards

• The need for stockholder approval for issuances exceeding 20% is standard practice under Nasdaq Rule 5635(d), aligning Microbot Medical with other listed companies.
• The terms of the Series I preferred investment options and Placement Agent Options, including exercise price, expiration date, and cashless exercise provisions, are generally consistent with market practices for similar securities.
• The company's decision to seek an increase in authorized shares is a common strategy employed by companies to maintain flexibility for future financing and strategic opportunities, similar to actions taken by other publicly traded companies in the medical device sector.

Stakeholder Impact

• Approval of the proposals will allow the company to fulfill its obligations to investors who participated in the recent offering.
• Existing stockholders will experience potential dilution if the options are exercised.
• The company's ability to raise capital in the future could be affected by the outcome of the vote on these proposals.

Next Steps

• Stockholders need to vote on the proposals before the April 10, 2025 deadline.
• The Special Meeting will be held on April 11, 2025, to count the votes and determine the outcome of the proposals.
• The company will report the voting results in a Current Report on Form 8-K within four business days after the conclusion of the Special Meeting.

Key Dates